



Another project brought to you by **GenomeCanada**

Pharmacogenomics of Drug Efficacy and Toxicity in the Treatment of Cardiovascular Disease

Integrated GE³LS Research

Current public policy lags in Pharmacogenomics research

GE³LS Project Leaders

Denise Avard and Yann Joly, Université de Montréal

Summary

The GE³LS research team will address issues of informed consent and knowledge transfer in the context of pharmacogenomics research.

Given the sheer number of human participants needed to conduct pharmacogenomic clinical trials, it is important to address the ethical, legal and social issues related to informed consent. This project will support the scientific activities of the GRID project by helping to develop meaningful consent processes that will enhance the informed nature of prospective consent and the protection of participants' rights. Issues of access to stored tissues, confidentiality and coding will be explored, as will the type of explanations given to research participants. Planned activities include developing academic papers and policy statements on the prospective nature of informed consent, patient confidentiality and governance of DNA banks; hosting a number of working group meetings with key stakeholders to enable exchange of views and perspectives across different disciplines; holding public events and developing a number of public education materials to inform the broader public community about pharmacogenomic research; and archiving all research outputs on the HUMGEN Website (www.humgen.umontreal.ca).

<http://www.genomequebec.com/GQGenomiqueSociete/projets/pharmacoEn.asp?l=e>